The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Myasthenia gravis: An emerging toxicity of immune checkpoint inhibitors
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766 · cited 1×
“Notably, CTLA-4 haploinsufficiency is associated with an autoimmune syndrome affecting multiple organs [26] and specifically, CTLA-4 knockout mice can spontaneously develop MG [27].”
BackgroundAssociation of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease
Ueda, H., Howson, J. M. M., Esposito, L., Heward, J., Snook, Chamberlain, G., Rainbow, D. B., Hunter, K. M. D., Smith, A. N., Di Genova, G., et al. (2003) · Nature · doi:10.1038/nature01621 · Cited by 2,175
Antonia, S. J., López-Martin, J. A., Bendell, J., Ott, P. A., Taylor, M., Eder, J. P., Jäger, D., Pietanza, M. C., Le, D. T., de Braud, F., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30098-5 · Cited by 1,244
Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity
Meriggioli, M. N., & Sanders, D. B. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70063-8 · Cited by 894
Management of toxicities of immune checkpoint inhibitors
Spain, L., Diem, S., & Larkin, J. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.02.001 · Cited by 854
Menzies, A. M., Johnson, D. B., Ramanujam, S., Atkinson, V. G., Wong, A. N. M., Park, J. J., McQuade, J. L., Shoushtari, A. N., Tsai, K. K., Eroglu, Z., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw443 · Cited by 817 · cited 2×
“In a study of 52 patients with significant autoimmune disorders who proceeded to receive a PD-1 inhibitor, 38% had a flare of their underlying autoimmune disorder [34].”
BackgroundResultT-cell exhaustion, co-stimulation and clinical outcome in autoimmunity and infection
McKinney, E. F., Lee, J. C., Jayne, D. R. W., Lyons, P. A., & Smith, K. G. C. (2015) · Nature · doi:10.1038/nature14468 · Cited by 685 · cited 1×
“With respect to PD-1, its overexpression is associated with favourable outcomes in autoimmune diseases as it potentiates CD8 T-cell exhaustion; hence, it is feasible that PD-1 inhibition could result in the exacerbation of symptoms in patients with pre-existing MG [31,32].”
BackgroundAntonia, S., Goldberg, S. B., Balmanoukian, A., Chaft, J. E., Sanborn, R. E., Gupta, A., Narwal, R., Steele, K., Gu, Y., Karakunnel, J. J., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00544-6 · Cited by 602 · cited 2×
“[15] Patient with advanced NSCLC treated with durvalumab þ tremelimumab Unknown Unknown 2 1 Unknown Unknown Yes”
BackgroundNeurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy
Zimmer, L., Goldinger, S. M., Hofmann, L., Loquai, C., Ugurel, S., Thomas, I., Schmidgen, M. I., Gutzmer, R., Utikal, J. S., Göppner, D., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.02.024 · Cited by 562
LINDSTROM, J. M., SEYBOLD, M. E., LENNON, V. A., WHITTINGHAM, S., & DUANE, D. D. (1998) · Neurology · doi:10.1212/wnl.51.4.933-a · Cited by 343
Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma
Liao, B., Shroff, S., Kamiya-Matsuoka, C., & Tummala, S. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou001 · Cited by 288
Myasthenic crisis and polymyositis induced by one dose of nivolumab
Kimura, T., Fukushima, S., Miyashita, A., Aoi, J., Jinnin, M., Kosaka, T., Ando, Y., Matsukawa, M., Inoue, H., Kiyotani, K., et al. (2016) · Cancer Science · doi:10.1111/cas.12961 · Cited by 192
Shirai, T., Sano, T., Kamijo, F., Saito, N., Miyake, T., Kodaira, M., Katoh, N., Nishie, K., Okuyama, R., & Uhara, H. (2015) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyv158 · Cited by 141
Myasthenia Gravis Induced by Ipilimumab in Patients With Metastatic Melanoma
Johnson, D. B., Saranga‐Perry, V., Lavin, P., Burnette, W. B., Clark, S. W., Uskavitch, D., Wallace, D. E., Dickson, M. A., Kudchadkar, R. R., & Sosman, J. A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.51.1683 · Cited by 112
Myasthenia triggered by immune checkpoint inhibitors: New case and literature review
Gonzalez, N. L., Puwanant, A., Lu, A., Marks, S. M., & Živković, S. (2017) · Neuromuscular Disorders · doi:10.1016/j.nmd.2017.01.002 · Cited by 103
Loochtan, A. I., Nickolich, M. S., & Hobson‐Webb, L. D. (2015) · Muscle & Nerve · doi:10.1002/mus.24648 · Cited by 101
Exacerbation of myasthenia gravis in a patient with melanoma treated with pembrolizumab
Lau, K. H. V., Kumar, A., Yang, I. H., & Nowak, R. J. (2016) · Muscle & Nerve · doi:10.1002/mus.25141 · Cited by 95
Wang, X., Pirskanen, R., Giscombe, R., & Lefvert, A. K. (2007) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2007.01879.x · Cited by 94
Checkpoint immunotherapy: good for cancer therapy, bad for rheumatic diseases
Calabrese, L. H., & Velcheti, V. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-209782 · Cited by 75
Pembrolizumab-induced myasthenia gravis: A fatal case report
March, K. L., Samarin, M. J., Sodhi, A., & Owens, R. E. (2017) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155216687389 · Cited by 73
A CTLA4high genotype is associated with myasthenia gravis in thymoma patients
Chuang, W., Ströbel, P., Gold, R., Nix, W. A., Schalke, B. C. G., Kiefer, R., Opitz, A., Klinker, E., Müller‐Hermelink, H. K., & Marx, A. (2005) · Annals of Neurology · doi:10.1002/ana.20577 · Cited by 69
Nguyen, B., Kuo, J. C.-Y., Budiman, A., Christie, H. R., & Ali, S. S. (2016) · Melanoma Research · doi:10.1097/cmr.0000000000000310 · Cited by 62
Nivolumab for the treatment of malignant melanoma in a patient with pre-existing myasthenia gravis.
Maeda, O., Yokota, K., Atsuta, N., Katsuno, M., Akiyama, M., & Ando, Y. (2016) · Europe PMC (PubMed Central) · doi:10.18999/nagjms.78.1.119 · Cited by 58
Myasthenia gravis induced by nivolumab therapy in a patient with non–small‐cell lung cancer
Polat, P., & Donofrio, P. D. (2016) · Muscle & Nerve · doi:10.1002/mus.25163 · Cited by 57
Phadke, S. D., Ghabour, R., Swick, B. L., Swenson, A., Milhem, M. M., & Zakharia, Y. (2016) · Journal of Investigative Medicine High Impact Case Reports · doi:10.1177/2324709616674316 · Cited by 54
Myasthenia gravis exacerbation associated with pembrolizumab
Zhu, J., & Li, Y. (2016) · Muscle & Nerve · doi:10.1002/mus.25055 · Cited by 53
Myasthenia Gravis After Nivolumab Therapy for Squamous Cell Carcinoma of the Bladder
Chang, E., Sabichi, A. L., & Sada, Y. H. (2017) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000161 · Cited by 51
Benign form of myasthenia gravis after nivolumab treatment
Sciacca, G., Nicoletti, A. S. Q., Rampello, L., Noto, L., Parra, H. J. S., & Zappia, M. (2016) · Muscle & Nerve · doi:10.1002/mus.25212 · Cited by 44
Alnahhas, I., & Wong, J. (2016) · Muscle & Nerve · doi:10.1002/mus.25496 · Cited by 37
Balance and Imbalance in the Immune System: Life on the Edge
Topalian, S. L., & Sharpe, A. H. (2014) · Immunity · doi:10.1016/j.immuni.2014.11.005 · Cited by 36
Sun, L., Meng, Y., Xie, Y., Zhang, H., Zhang, Z., Wang, X., Jiang, B., Li, W., Li, Y., & Yang, Z. (2014) · PLoS ONE · doi:10.1371/journal.pone.0101986 · Cited by 33
Cited by
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
Martins, F., Sofiya, L., Sykiotis, G. P., Lamine, F., Maillard, M., Fraga, M., Shabafrouz, K., Ribi, C., Cairoli, A., Guex-Crosier, Y., et al. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0218-0 · Cited by 2,314
Immune-related adverse events of checkpoint inhibitors
Ramos-Casals, M., Brahmer, J. R., Callahan, M. K., Flores-Chávez, A., Keegan, N., Khamashta, M. A., Lambotte, O., Mariette, X., Prat, A., & Suárez-Almazor, M. E. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0160-6 · Cited by 1,412
International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update
Narayanaswami, P., Sanders, D. B., Wolfe, G., Benatar, M., Cea, G., Evoli, A., Gilhus, N. E., Illa, I., Kuntz, N. L., Massey, J., et al. (2021) · Neurology · doi:10.1212/wnl.0000000000011124 · Cited by 813
Thompson, J. A., Schneider, B. J., Brahmer, J., Andrews, S., Armand, P., Bhatia, S., Budde, L. E., Costa, L., Davies, M., Dunnington, D., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.0013 · Cited by 570
Immune Checkpoint Immunotherapy for Non-Small Cell Lung Cancer
Suresh, K., Naidoo, J., Lin, C. T., & Danoff, S. (2018) · Chest · doi:10.1016/j.chest.2018.08.1048 · Cited by 379
Metadata
- Authors
- Makarious, D., Horwood, K., & Coward, J. I. G.
- Venue
- European Journal of Cancer
- Publisher
- Elsevier BV
- Published
- 2017-09
- Volume
- 82
- Pages
- 128-136
- ISSN
- 0959-8049 (ISSN-L)
- OpenAlex
- W2676820279
- Cited by
- 262
- References
- 32
- FWCI
- 13.68
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.